Universidad Austral de Chile Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2006
NCT00749645
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

Aravena, Pedro, DDS, PhD | Juan C. Bertoglio, MD | Universidad Austral de Chile

Active Ingredients

Drugs in Phase 3 Trials (1)

m. sylvestris extract (1 trial)

Drugs in Phase 2 Trials (2)

andrographolide (2 trials)

fang(30) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Chronic Progressive (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 3